Latest Insider Transactions at Clene Inc. (CLNN)
This section provides a real-time view of insider transactions for Clene Inc. (CLNN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Clene Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Clene Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 02
2022
|
Chidozie Ugwumba > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
990,099
+15.21%
|
$990,099
$1.01 P/Share
|
|
Aug 17
2022
|
John Henry Stevens |
BUY
Open market or private purchase
|
Direct |
47,662
+12.45%
|
$142,986
$3.85 P/Share
|
|
Jul 18
2022
|
Robert Dee Etherington President & CEO |
SELL
Open market or private sale
|
Direct |
23,483
-29.33%
|
$93,932
$4.72 P/Share
|
|
Jun 17
2022
|
David J Matlin Director |
BUY
Open market or private purchase
|
Direct |
74,610
+2.99%
|
$149,220
$2.51 P/Share
|
|
Jun 16
2022
|
David J Matlin Director |
BUY
Open market or private purchase
|
Direct |
75,000
+3.1%
|
$150,000
$2.5 P/Share
|
|
Jun 16
2022
|
Mark Mortenson Chief Science Officer |
SELL
Open market or private sale
|
Direct |
20,247
-10.71%
|
$40,494
$2.47 P/Share
|
|
Jun 15
2022
|
Alison Mosca Director |
BUY
Open market or private purchase
|
Direct |
5,000
+11.24%
|
$10,000
$2.62 P/Share
|
|
Jun 15
2022
|
David J Matlin Director |
BUY
Open market or private purchase
|
Direct |
45,000
+1.94%
|
$90,000
$2.66 P/Share
|
|
Jun 14
2022
|
David J Matlin Director |
BUY
Open market or private purchase
|
Direct |
51,011
+2.24%
|
$102,022
$2.66 P/Share
|
|
Jun 13
2022
|
David J Matlin Director |
BUY
Open market or private purchase
|
Direct |
55,000
+2.46%
|
$165,000
$3.06 P/Share
|
|
Jun 06
2022
|
David J Matlin Director |
BUY
Open market or private purchase
|
Direct |
50,670
+2.33%
|
$101,340
$2.57 P/Share
|
|
Jun 03
2022
|
David J Matlin Director |
BUY
Open market or private purchase
|
Direct |
10,000
+0.48%
|
$20,000
$2.46 P/Share
|
|
May 27
2022
|
David J Matlin Director |
BUY
Open market or private purchase
|
Direct |
35,000
+1.67%
|
$70,000
$2.27 P/Share
|
|
May 16
2022
|
Robert Glanzman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,717
-30.87%
|
$9,434
$2.03 P/Share
|
|
May 16
2022
|
David J Matlin Director |
BUY
Open market or private purchase
|
Direct |
181,818
+8.23%
|
$363,636
$2.2 P/Share
|
|
May 16
2022
|
General Resonance LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
181,818
-1.16%
|
$363,636
$2.2 P/Share
|
|
May 16
2022
|
Jonathon Gay Director |
BUY
Open market or private purchase
|
Direct |
10,000
+12.7%
|
$20,000
$2.08 P/Share
|
|
May 02
2022
|
Reed N Wilcox Director |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+19.99%
|
$0
$0.15 P/Share
|
|
Apr 21
2022
|
General Resonance LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
132,891
-0.84%
|
$398,673
$3.01 P/Share
|
|
Apr 20
2022
|
David J Matlin Director |
BUY
Open market or private purchase
|
Direct |
132,891
+6.72%
|
$398,673
$3.01 P/Share
|
|
Mar 29
2022
|
David J Matlin Director |
BUY
Open market or private purchase
|
Direct |
8,648
+0.5%
|
$25,944
$3.23 P/Share
|
|
Mar 28
2022
|
David J Matlin Director |
BUY
Open market or private purchase
|
Direct |
10,000
+0.58%
|
$30,000
$3.1 P/Share
|
|
Mar 24
2022
|
David J Matlin Director |
BUY
Open market or private purchase
|
Direct |
20,000
+1.17%
|
$40,000
$2.99 P/Share
|
|
Mar 23
2022
|
David J Matlin Director |
BUY
Open market or private purchase
|
Direct |
20,000
+1.18%
|
$40,000
$2.94 P/Share
|
|
Mar 21
2022
|
David J Matlin Director |
BUY
Open market or private purchase
|
Direct |
35,000
+2.07%
|
$70,000
$2.9 P/Share
|
|
Mar 18
2022
|
David J Matlin Director |
BUY
Open market or private purchase
|
Direct |
20,000
+1.22%
|
$40,000
$2.79 P/Share
|
|
Feb 17
2022
|
John Henry Stevens |
BUY
Exercise of conversion of derivative security
|
Direct |
273,194
+48.72%
|
$0
$0.53 P/Share
|
|
Feb 01
2022
|
General Resonance LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
101,352
-0.63%
|
$202,704
$2.96 P/Share
|
|
Feb 01
2022
|
David J Matlin Director |
BUY
Open market or private purchase
|
Direct |
101,352
+5.97%
|
$202,704
$2.96 P/Share
|
|
Jan 20
2022
|
Reed N Wilcox Director |
BUY
Exercise of conversion of derivative security
|
Direct |
253,000
+45.73%
|
$0
$0.15 P/Share
|
|
Dec 31
2021
|
Chidozie Ugwumba > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
4,528,809
+50.0%
|
-
|
|
Dec 10
2021
|
David J Matlin Director |
BUY
Open market or private purchase
|
Direct |
15,000
+0.99%
|
$60,000
$4.87 P/Share
|
|
Dec 09
2021
|
David J Matlin Director |
BUY
Open market or private purchase
|
Direct |
40,000
+2.63%
|
$200,000
$5.0 P/Share
|
|
Dec 08
2021
|
David J Matlin Director |
BUY
Open market or private purchase
|
Direct |
5,000
+0.35%
|
$20,000
$4.93 P/Share
|
|
Dec 06
2021
|
David J Matlin Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
50,000
+25.0%
|
$0
$0.01 P/Share
|
|
Dec 06
2021
|
David J Matlin Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
12,500
+0.86%
|
$0
$0.01 P/Share
|
|
Nov 16
2021
|
David J Matlin Director |
BUY
Open market or private purchase
|
Direct |
20,000
+1.39%
|
$100,000
$5.26 P/Share
|
|
Nov 15
2021
|
David J Matlin Director |
BUY
Open market or private purchase
|
Direct |
15,000
+1.06%
|
$75,000
$5.71 P/Share
|
|
Nov 12
2021
|
David J Matlin Director |
BUY
Open market or private purchase
|
Direct |
10,000
+0.71%
|
$50,000
$5.37 P/Share
|
|
Oct 01
2021
|
Alison Mosca Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
25,000
+0.59%
|
$0
$0.01 P/Share
|
|
Jul 14
2021
|
John Henry Stevens |
BUY
Grant, award, or other acquisition
|
Direct |
14,378
+50.0%
|
-
|
|
Jul 14
2021
|
Alison Mosca Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,083
+50.0%
|
-
|
|
Jul 14
2021
|
Shalom Jacobovitz Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,838
+50.0%
|
-
|
|
Jul 14
2021
|
Jonathon Gay Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,783
+50.0%
|
-
|
|
Jul 14
2021
|
Reed N Wilcox Director |
BUY
Grant, award, or other acquisition
|
Direct |
27,784
+50.0%
|
-
|
|
Jun 30
2021
|
Robert Dee Etherington President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
80,076
+50.0%
|
-
|
|
Jun 30
2021
|
Mark Mortenson Chief Science Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,082
+50.0%
|
-
|
|
Jun 30
2021
|
Robert Glanzman Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,281
+50.0%
|
-
|
|
May 24
2021
|
David J Matlin Director |
BUY
Open market or private purchase
|
Direct |
207,684
+13.09%
|
$1,869,156
$9.63 P/Share
|
|
May 24
2021
|
Alison Mosca Director |
BUY
Open market or private purchase
|
Indirect |
51,921
+50.0%
|
$467,289
$9.63 P/Share
|